Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $5.2300 (-3.33%) ($5.0600 - $5.4000) on Thu. Nov. 8, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.57% (three month average) | RSI | 47 | Latest Price | $5.2300(-3.33%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1.2% a day on average for past five trading days. | Weekly Trend | TGTX advances 0.8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) IGOV(7%) BND(4%) BNDX(4%) IPO(4%) KWEB(4%) | Factors Impacting TGTX price | TGTX will decline at least -3.285% in a week (0% probabilities). URA(-7%) XME(-6%) XLB(-5%) VFMO(-5%) XLF(-4%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.285% (StdDev 6.57%) | Hourly BBV | 0 () | Intraday Trend | -3.1% | | | |
|
5 Day Moving Average | $5.15(1.55%) | 10 Day Moving Average | $4.91(6.52%) | 20 Day Moving Average | $5.13(1.95%) | To recent high | -58.8% | To recent low | 3.2% | Market Cap | $662m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |